Cotreatment with methotrexate in routine care patients with rheumatoid arthritis receiving biological treatment yields better outcomes over time

Objectives We aimed to evaluate the effects of methotrexate (MTX) comedication added to biological disease-modifying antirheumatic drugs (bDMARD) on disease activity measures in patients with rheumatoid arthritis (RA) in routine care. Methods Patients with RA on treatment with either bDMARDs or conv...

Full description

Bibliographic Details
Main Author: Boone, Niels W. (author)
Other Authors: Sepriano, Alexandre (author), Van Der Kuy, Paul Hugo (author), Janknegt, Rob (author), Peeters, Ralph (author), Landewé, Robert B.M. (author)
Format: article
Language:eng
Published: 2019
Subjects:
DAS28
DMARDs (biologic)
methotrexate
patient reported outcome measure (PROM)
rheumatoid arthritis
Rheumatology
Immunology and Allergy
Immunology
Online Access:https://doi.org/10.1136/rmdopen-2018-000836
Country:Portugal
Oai:oai:run.unl.pt:10362/60028

Internet

https://doi.org/10.1136/rmdopen-2018-000836

Similar Items